Neuroprotective effect of mesenchymal stem cell through complement component 3 downregulation after transient focal cerebral ischemia in mice

Neuroscience Letters

Volumn 633, Issue , 2016, Pages 227-234

  Jung, Hye Seon ^a   Jeong, Si Yeon ^a   Yang, Jiwon ^a   Kim, So Dam ^a   Zhang, Baojin ^a   Yoo, Hyun Seung ^b   Song, Sun U ^b   Jeon, Myung Shin ^b,c   Song, Yun Seon ^a  

^a Sookmyung Women's University   (South Korea)

^b Inha Research Institute of Medical Sciences   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

Cerebral ischemia; Complement component 3; Mesenchymal stem cell; Neuroprotection; Oxygen glucose deprivation

Indexed keywords

COMPLEMENT COMPONENT C3; CXCL2 CHEMOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMA PROTEIN; PROTEIN TSG6; UNCLASSIFIED DRUG; CYTOKINE; GLUCOSE; MICROTUBULE ASSOCIATED PROTEIN; OXYGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN INFARCTION SIZE; BRAIN SIZE; CELL MATURATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; MALE; MESENCHYMAL STEM CELL; MOUSE; NERVE CELL; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSIENT FOCAL CEREBRAL ISCHEMIA; TRANSIENT ISCHEMIC ATTACK; ANIMAL; BRAIN CORTEX; CELL HYPOXIA; CEREBRAL INFARCTION; DEFICIENCY; ISCHEMIC ATTACK, TRANSIENT; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY;

ANIMALS; CELL HYPOXIA; CEREBRAL CORTEX; CEREBRAL INFARCTION; COMPLEMENT C3; CYTOKINES; DOWN-REGULATION; GLUCOSE; ISCHEMIC ATTACK, TRANSIENT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; OXYGEN;

EID: 84989210996     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.09.032     Document Type: Article

References (34)

1. [1] Doeppner, T.R., Hermann, D.M., Stem cell-based treatments against stroke: observations from human proof-of-concept studies and considerations regarding clinical applicability. Front. Cell. Neurosci. 8 (2014), 357–362.
2. [2] Chen, J., Chopp, M., Neurorestorative treatment of stroke: cell and pharmacological approaches. NeuroRx 3 (2006), 466–473.
3. [3] Eckert, M.A., Vu, Q., Xie, K., Yu, J., Liao, W., Cramer, S.C., Zhao, W., Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J. Cereb. Blood Flow Metab. 33 (2013), 1322–1334.
4. [4] Chen, X., Li, Y., Wang, L., Katakowski, M., Zhang, L., Chen, J., Xu, Y., Gautam, S.C., Chopp, M., Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology 22 (2002), 275–279.
5. [5] Zhang, L., Li, Y., Zhang, C., Chopp, M., Gosiewska, A., Hong, K., Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke 42 (2011), 1437–1444.
6. [6] Azari, M.F., Mathias, L., Ozturk, E., Cram, D.S., Boyd, R.L., Petratos, S., Mesenchymal stem cells for treatment of CNS injury. Curr. Neuropharmacol. 8 (2010), 316–323.
7. [7] Prockop, D.J., Oh, J.Y., Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol. Ther. 20 (2012), 14–20.
8. [8] Trounson, A., New perspectives in human stem cell therapeutic research. BMC Med., 7, 2009, 29.
9. [9] Lindsberg, P.J., Grau, A.J., Inflammation and infections as risk factors for ischemic stroke. Stroke 34 (2003), 2518–2532.
10. [10] Hurn, P.D., Subramanian, S., Parker, S.M., Afentoulis, M.E., Kaler, L.J., Vandenbark, A.A., Offner, H., T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J. Cereb. Blood Flow Metab. 27 (2007), 1798–1805.
11. [11] Gasque, P., Ischenko, A., Legoedec, J., Mauger, C., Schouft, M.T., Fontaine, M., Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. J. Biol. Chem. 268 (1993), 25068–25074.
12. [12] Nataf, S., Stahel, P.F., Davoust, N., Barnum, S.R., Complement anaphylatoxin receptors on neurons: new tricks for old receptors?. Trends Neurosci. 22 (1999), 397–402.
13. [13] Arumugam, T.V., Shiels, I.A., Woodruff, T.M., Granger, D.N., Taylor, S.M., The role of the complement system in ischemia-reperfusion injury. Shock 21 (2004), 401–409.
14. [14] Cojocaru, I.M., Cojocaru, M., Tanasescu, R., Burcin, C., Atanasiu, A.N., Petrescu, A.M., Mitu, A.C., Iliescu, I., Dumitrescu, L., Changes in plasma levels of complement in patients with acute ischemic stroke. Rom. J. Intern. Med. 46 (2008), 77–80.
15. [15] Sahu, A., Lambris, J.D., Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180 (2001), 35–48.
16. [16] Arumugam, T.V., Woodruff, T.M., Lathia, J.D., Selvaraj, P.K., Mattson, M.P., Taylor, S.M., Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 158 (2009), 1074–1089.
17. [17] Mocco, J., Mack, W.J., Ducruet, A.F., Sosunov, S.A., Sughrue, M.E., Hassid, B.G., Nair, M.N., Laufer, I., Komotar, R.J., Claire, M., Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ. Res. 99 (2006), 209–217.
18. [18] Yang, J., Ahn, H.N., Chang, M., Narasimhan, P., Chan, P.H., Song, Y.S., Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J. Neurochem. 124 (2013), 523–535.
19. [19] Le Blanc, K., Mougiakakos, D., Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 12 (2012), 383–396.
20. [20] Ma, S., Zhong, D., Chen, H., Zheng, Y., Sun, Y., Luo, J., Li, H., Li, G., Yin, Y., The immunomodulatory effect of bone marrow stromal cells (BMSCs) on interleukin (IL)-23/IL-17-mediated ischemic stroke in mice. J. Neuroimmunol. 257 (2013), 28–35.
21. [21] Gelderblom, M., Weymar, A., Bernreuther, C., Velden, J., Arunachalam, P., Steinbach, K., Orthey, E., Arumugam, T.V., Leypoldt, F., Simova, O., Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood 120:2012 (2012), 3793–3802.
22. [22] An, C., Shi, Y., Li, P., Hu, X., Gan, Y., Stetler, R.A., Leak, R.K., Gao, Y., Sun, B.L., Zheng, P., Chen, J., Molecular dialogs between the ischemic brain and the peripheral immune system: dualisticroles in injury and repair. Prog. Neurobiol. 115 (2014), 6–24.
23. [23] Suzuki, S., Tanaka, K., Suzuki, N., Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects. J. Cereb. Blood Flow Metab. 29 (2009), 464–479.
24. [24] Yamashita, T., Sawamoto, K., Suzuki, S., Suzuki, N., Adachi, K., Kawase, T., Mihara, M., Ohsugi, Y., Abe, K., Okano, H., Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J. Neurochem. 94 (2005), 459–468.
25. [25] Swartz, K.R., Liu, F., Sewell, D., Schochet, T., Campbell, I., Sandor, M., Fabry, Z., Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res. 896 (2011), 86–95.
26. [26] Matsuda, S., Wen, T.C., Morita, F., Otsuka, H., Igase, K., Yoshimura, H., Sakanaka, M., Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils. Neurosci. Lett. 204 (1996), 109–112.
27. [27] Stowe, A.M., Wacker, B.K., Cravens, P.D., Perfater, J.L., Li, M.K., Hu, R., Freie, A.B., Stuve, O., Gidday, J.M., CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke. J. Neuroinflammation 9 (2012), 33–44.
28. [28] Liu, Y., Zhang, R., Yan, K., Chen, F., Huang, W., Lv, B., Sun, C., Xu, L., Li, F., Jiang, X., Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6. J. Neuroinflammation 11 (2014), 135–146.
29. [29] Tuo, J., Cao, X., Shen, D., Wang, Y., Zhang, J., Oh, J.Y., Prockop, D.J., Chan, C.C., Anti-inflammatory recombinant TSG-6 stabilizes the progression of focal retinal degeneration in a murine model. J. Neuroinflammation 9 (2012), 127–139.
30. [30] Shichita, T., Sugiyama, Y., Ooboshi, H., Sugimori, H., Nakagawa, R., Takada, I., Iwaki, T., Okada, Y., Iida, M., Cua, D.J., Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat. Med. 15 (2009), 946–950.
31. [31] Tate, C.C., Fonck, C., McGrogan, M., Case, C.C., Human mesenchymal stromal cells and their derivative SB623 cells, rescue neural cells via trophic support following in vitro ischemia. Cell Transplant. 19 (2010), 973–984.
32. [32] Song, W.C., Sarrias, M.R., Lambris, J.D., Complement and innate immunity. Immunopharmacol. 49 (2000), 187–198.
33. [33] Tu, Z., Li, Q., Bu, H., Lin, F., Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 19 (2010), 1803–1809.
34. [34] Lian, H., Yang, L., Cole, A., Sun, L., Chiang, A.C., Fowler, S.W., Shim, D.J., Rodriguez-Rivera, J., Taglialatela, G., Jankowsky, J.L., Lu, H.C., Zheng, H., NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron 85 (2015), 101–115.